Severe Asthma: Clinical Trials

3 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 6 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	6	Recruiting 3, Active not recruiting 1, Completed 1, Not yet recruiting 1

Follow Severe Asthma: new trials by email Literature Review of Severe Asthma trials Research Report on Severe Asthma

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab Tezepelumab - Severe Asthma	Phase 3	Recruiting	AstraZeneca	400	2026-01-28	2026-09-03
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) GB-0895, Placebo - Severe Asthma	Phase 3	Recruiting	Generate Biomedicines	786	2026-01-20	2026-10-20
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) GB-0895, Placebo - Severe Asthma	Phase 3	Recruiting	Generate Biomedicines	786	2025-12-03	2026-10-22
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab Tezepelumab, Acarizax, Placebo - Severe Asthma, Allergy to House Dust Mites	Phase 3	Not yet recruiting	University Hospital, Montpellier	38	2025-07-15	2025-06-10
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®) - Severe Asthma	Phase 3	Active not recruiting	AstraZeneca	310	2024-09-30	2026-10-13
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma Biological: Experimental: Tezepelumab - Severe Asthma	Phase 3	Completed	AstraZeneca	65	2019-06-10	2022-06-01

Narrower conditions

Asthma (6)  ·  Dust Mite Allergy (1)

Broader conditions

Bronchial Diseases (6)  ·  Hypersensitivity (6)  ·  Hypersensitivity, Immediate (6)  ·  Immune System Diseases (6)  ·  Lung Diseases (6)  ·  Lung Diseases, Obstructive (6)  ·  Respiratory Hypersensitivity (6)  ·  Respiratory Tract Diseases (6)  ·  Nose Diseases (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Rhinitis (1)  ·  Rhinitis, Allergic (1)  ·  Rhinitis, Allergic, Perennial (1)

Interventions

tezepelumab (4)  ·  Albuterol (1)  ·  Budesonide (1)  ·  Budesonide, Formoterol Fumarate Drug Combination (1)  ·  Mannitol (1)

Sponsors

AstraZeneca (3)  ·  Generate Biomedicines (2)  ·  University Hospital, Montpellier (1)

Countries

United States (3)  ·  Argentina (2)  ·  Belgium (2)  ·  Bulgaria (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  Brazil (1)  ·  Canada (1)  ·  Chile (1)  ·  China (1)

Top investigators

FengMing Luo, Professor (1)  ·  KeFang Lai, Professor (1)  ·  Masaharu Shinkai, MD (1)

NIH funding

2025 (1)